JP2005512996A - 乳癌の治療 - Google Patents

乳癌の治療 Download PDF

Info

Publication number
JP2005512996A
JP2005512996A JP2003541817A JP2003541817A JP2005512996A JP 2005512996 A JP2005512996 A JP 2005512996A JP 2003541817 A JP2003541817 A JP 2003541817A JP 2003541817 A JP2003541817 A JP 2003541817A JP 2005512996 A JP2005512996 A JP 2005512996A
Authority
JP
Japan
Prior art keywords
breast cancer
patient
chemotherapeutic agent
patients
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2003541817A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005512996A5 (https=
Inventor
マーク ヴィンセント、
ローン ジェイ． ブランデス、
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Manitoba
Gilead YM ULC
Original Assignee
University of Manitoba
YM Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Manitoba, YM Biosciences Inc filed Critical University of Manitoba
Publication of JP2005512996A publication Critical patent/JP2005512996A/ja
Publication of JP2005512996A5 publication Critical patent/JP2005512996A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2003541817A 2001-11-09 2002-11-06 乳癌の治療 Withdrawn JP2005512996A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33114201P 2001-11-09 2001-11-09
US40724102P 2002-09-03 2002-09-03
PCT/CA2002/001725 WO2003039526A1 (en) 2001-11-09 2002-11-06 Treatment of breast cancer

Publications (2)

Publication Number Publication Date
JP2005512996A true JP2005512996A (ja) 2005-05-12
JP2005512996A5 JP2005512996A5 (https=) 2006-01-05

Family

ID=26987607

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003541817A Withdrawn JP2005512996A (ja) 2001-11-09 2002-11-06 乳癌の治療

Country Status (5)

Country Link
US (1) US20050119263A1 (https=)
EP (1) EP1441711A1 (https=)
JP (1) JP2005512996A (https=)
CA (1) CA2465916A1 (https=)
WO (1) WO2003039526A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012523828A (ja) * 2009-04-17 2012-10-11 ユニヴェルシテ リブル ドゥ ブリュッセル ガンにおけるアントラサイクリン系薬剤の効率を予測するための方法およびツール

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003269621A1 (en) * 2002-09-03 2004-03-29 Lorne J. Brandes Neoadjuvant treatment of breast cancer
CA2497180A1 (en) * 2002-09-04 2004-03-18 The University Of Manitoba Treatment of metastatic breast cancer with anthracyclines, taxanes and an histamine antagonist
CN1703212A (zh) * 2002-09-11 2005-11-30 马尼托巴大学 Dppe与其它化学治疗剂联合治疗乳腺癌的用途
US20110195848A1 (en) * 2010-01-08 2011-08-11 Roopra Avtar S Gene expression and breast cancer
BR112017015013A2 (pt) 2015-01-19 2018-01-23 Belina Pharma Ab anti-histamina para uso no tratamento de câncer da mama

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1229604A (en) * 1984-02-14 1987-11-24 Lorne J. Brandes Aminoalkyl ethers of phenols as antiproliferative anticancer agents
US5798339A (en) * 1990-12-17 1998-08-25 University Of Manitoba Treatment method for cancer
US5618846A (en) * 1990-12-17 1997-04-08 University Of Manitoba Treatment method for cancer
ES2063574T3 (es) * 1990-12-17 1995-01-01 Univ Manitoba Metodo de tratamiento mejorado para el cancer.
US6284799B1 (en) * 1994-02-17 2001-09-04 University Of Manitoba Cancer treatment

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012523828A (ja) * 2009-04-17 2012-10-11 ユニヴェルシテ リブル ドゥ ブリュッセル ガンにおけるアントラサイクリン系薬剤の効率を予測するための方法およびツール

Also Published As

Publication number Publication date
WO2003039526A1 (en) 2003-05-15
CA2465916A1 (en) 2003-05-15
US20050119263A1 (en) 2005-06-02
EP1441711A1 (en) 2004-08-04

Similar Documents

Publication Publication Date Title
Rao et al. A phase II trial of imatinib mesylate in patients with prostate specific antigen progression after local therapy for prostate cancer
CN109310754A (zh) 使用包含抗erbb3抗体的联合疗法治疗er+、her2-、hrg+乳腺癌的方法
CN105916501A (zh) 用于治疗局部晚期或转移性雌激素受体阳性乳腺癌的雌激素受体调节剂
Warner et al. Phase II study of dexverapamil plus anthracycline in patients with metastatic breast cancer who have progressed on the same anthracycline regimen.
Margolin et al. Phase II study of carmustine, dacarbazine, cisplatin, and tamoxifen in advanced melanoma: a Southwest Oncology Group study.
EP3302478B1 (en) Pac-1 combination therapy
JP2005512996A (ja) 乳癌の治療
JP7278405B2 (ja) 小細胞肺がんの治療におけるキアウラニブの使用
JP2006523664A5 (https=)
Karacetin et al. Concomitant temozolomide and radiotherapy versus radiotherapy alone for treatment of newly diagnosed glioblastoma multiforme
WO2024165068A1 (zh) 取代2-氢-吡唑衍生物的联用药物组合物及其用途
Lentz Endocrine therapy of endometrial cancer
AU2002340668A1 (en) Treatment of breast cancer
US20060142287A1 (en) Use of a combination of dppe with other chemotherapeutic agents for the treatment of breast cancer
KR20080034151A (ko) 암 치료를 위한 조스퀴다르, 다우노루비신 및 시타라빈
WO2024246824A1 (en) Methods and modified dosing regimens comprising a cdk4 inhibitor for the treatment of cancer
US20080318880A1 (en) Neoadjuvant treatment of Breast Cancer
JP2005512983A (ja) 癌治療におけるｎ，ｎ−ジエチル−２−［−４−（フェニルメチル）−フェノキシ］エタナミンモノハイドロクロライド（ｄｐｐｅ）の使用
WO2022123419A1 (en) Treatment of luminal subtypes of hr-positive, her2-negative early breast cancer with palbociclib
WO2026039849A1 (en) Nuclear transport inhibitors for anti-cancer combination therapy
US20060089317A1 (en) Treatment of metastatic breast cancer with anthracyclines, and taxanes
JP2005507410A (ja) Ｂｃｒ／ａｂｌキナーゼ活性のＡＴＰ競合的阻害剤とチロホスチンアナログとの組合せ剤
Erkişi et al. Adjuvant use of antiprolactin, antiestrogen, and cytotoxic chemotherapy for breast cancer
WO2004022044A1 (en) Use of a combination of a taxane with dppe for the treatment of cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20051107

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20051107

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20071016